BHF backs vitamin K heart health research

By Shane Starling

- Last updated on GMT

© iStock
© iStock
The British Heart Foundation (BHF) has invested £290,000 (€365,000) in a vitamin K trial investigating its potential to reduce heart problems in people with chronic kidney disease (CKD).

The University of Dundee and University of Glasgow in Scotland are looking at the potential of vitamin K to reduce blood vessel calcium build up that is common in those with kidney disease, and which can provoke heart attacks and strokes.

The study is comprised of 166 CKD sufferers who will be given either 400 micrograms of vitamin K or placebo.

“This BHF-funded trial will test whether a simple treatment, vitamin K supplementation, can reduce the development of arterial stiffness – an early sign of cardiovascular risk,”​ said professor Jeremy Pearson, BHF associate medical director.

If successful, it will pave the way for a large scale trial to find out whether vitamin K supplementation reduces cardiovascular events in CKD patients and therefore should become part of routine treatment.”

About a third of over-65s have CKD in the UK.

Related news

Show more

Related products

show more

Aquamin demonstrates superior bioavailability.

Aquamin demonstrates superior bioavailability.

Marigot Ltd | 22-Nov-2017 | Technical / White Paper

Aquamin has proven superior bioavailability vs. other typical calcium sources in number of peer-reviewed published studies. Recent publication demonstrates...

Related suppliers

1 comment

Choose the right K

Posted by J. H. Berthelsen,

Vitamin K2 is probably the best K for this purpose.

Report abuse

Follow us

Featured Events

View more

Products

View more

Webinars